Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

bution from Bioniche Pharma, which was acquired in September 2010.  

Third party net sales from EMEA were $397.0 million for the quarter ended December 31, 2010, compared to $476.6 million for the comparable prior year quarter, a decrease of $79.6 million, or 16.7%. However, translating current quarter third party net revenues from EMEA at prior year exchange rates would have resulted in a year-over-year decrease excluding the effect of foreign currency of approximately $48 million, or 10%. This decrease was mainly the result of unfavorable pricing in many of the European markets in which Mylan operates and the lack of a significant product launch, partially offset by another strong quarter of performance in Italy.

Sales in Asia Pacific are derived from Mylan's operations in India, Australia, Japan and New Zealand. Asia Pacific third party net sales were $305.1 million for the quarter ended December 31, 2010, compared to $269.2 million for the comparable prior year quarter, an increase of $36.0 million, or 13.4%. Foreign currency translation had a positive impact on sales for the current quarter, reflecting the strengthening of certain regional currencies against the U.S. Dollar. Excluding the effect of foreign currency, calculated as described above, the increase was approximately $18 million, or 7%. This increase is primarily driven by increased sales of anti-retroviral finished dosage products and higher sales of active pharmaceutical ingredients (API) by Mylan's subsidiary in India.

For the current quarter, Specialty reported third party net sales of $75.0 million, an increase of $18.6 million, or 33%, from the comparable prior year period of $56.3 million. The most significant contributor to Specialty Segment revenues continues to be the EpiPen® Auto-Injector.  In the current quarter, Specialty realized increased sales of the EpiPen Auto-Injector, mainly as a result of favorable pricing and increased volumes.

Gros
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR ... December 22, 2014, thereby completing the U.S. HSR ... acquisition of the Company by Merck KGaA, Darmstadt, ... another condition to closing the transaction, which remains ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Graphene, a one-atom thick sheet of carbon ... "wonder material" that has taken scientific communities and ... material properties, such as high current-carrying capacity and ... components for semiconductor circuits and computers. Moreover, it ...
... improve photoelectrochemical cells. In the same way that plants ... use sunlight to drive chemical reactions that ultimately produce ... semi-conducting material such as cuprous oxide to provide the ... not expensive, the oxide is unstable if exposed to ...
... BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... financial results for the first quarter ended March 31, 2011 ... reported a net income of $3.7 million or $0.59 per ... diluted basis. The Company anticipates that it will be profitable ...
Cached Biology Technology:Why graphene holds the key to the future 2Harnessing the energy of the Sun: New technique improves artificial photosynthesis 2BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results 2BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results 3BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results 4BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results 5BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results 6BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results 7BioSpecifics Technologies Corp. Reports First Quarter 2011 Financial Results 8
(Date:12/10/2014)... 8, 2014 You,ve been here before: you desperately ... remember your password, site key or the answer to your ... grade teacher? Today, Hoyos Labs , ... that will finally put an end to the frustration that ... . 1U leverages a user,s smartphone to acquire his ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... U.S. is produced by coal. Yet this power leaves behind ... College of Engineering at the University of Tennessee, Knoxville, has ... change that. Peter Liaw, professor and Ivan ... colleagues have received a $300,000 Clean Coal Research Award for ...
... this year,s Gulf of Mexico hypoxic zone could range from ... as 6,213 square miles. The wide range is the result ... on Mississippi River nutrient inputs compiled annually by the U.S. ... covering an area slightly larger than the state of Rhode ...
... been announced as the overall winner in this year,s Wellcome Image ... during a surgical procedure to treat a patient with epilepsy, the ... Professor Alice Roberts, who was a member of the judging panel, ... makes it so different from most images of the surface of ...
Cached Biology News:University of Tennessee professor receives funding for clean coal research 2NOAA: Gulf of Mexico 'dead zone' predictions feature uncertainty 2NOAA: Gulf of Mexico 'dead zone' predictions feature uncertainty 3Photograph of a living human brain is the overall winner of Wellcome Image Awards 2012 2
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... Synthetic peptide derived from the C-terminal ... Specificity: Reacts with the human ... Human Mouse (positive controls: WNT1-transfected HEK293 ... and mouse Mouse-1 cell lysates). ...
Biology Products: